All Oncology News

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

The FDA has granted fast track designation to OBX-115 for advanced melanoma that is refractory to or relapsed after immune checkpoint inhibitors.

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

The BLA seeking approval for remestemcel-L for children with steroid-refractory acute graft-vs-host-disease has been resubmitted to the FDA.

Elevar Therapeutics plans to resubmit a new drug application for rivoceranib plus camrelizumab for first-line unresectable hepatocellular carcinoma.

Maurie Markman, MD, details the concept of hope during cancer diagnoses, touching on the announcement from Catherine, Princess of Wales.

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.

The FDA has granted fast track designation to BNT324/DB-1311 for metastatic castration-resistant prostate cancer.

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.

China’s NMPA has granted priority review to an NDA for tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma.

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

The FDA has granted fast track designation to ADI-270 for advanced clear cell renal cell carcinoma after an immune checkpoint inhibitor and VEGF inhibitor.

Frontline osimertinib plus chemotherapy has been approved in the European Union for adult patients with advanced EGFR-mutated non–small cell lung cancer.

First-line tiragolumab plus atezolizumab and chemotherapy failed to improve survival in advanced nonsquamous non–small cell lung cancer.

Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.

Assistant professor Lucia Borriello, of Fox Chase Cancer Center, was recently elected to the Board of Directors for the Metastasis Research Society.

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, addressing the heightened cancer risk faced by firefighters.

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

Temple University Hospital has received re-accreditation under the American College of Surgeons, Commission on Cancer Accreditation Program.

Chih-Yi Liao, MD, discusses treatment considerations for patients with hepatocellular carcinoma and emphasizes the need for a multidisciplinary approach.

Anjana Pillai, MD, detailed how the treatment landscape for HCC is evolving, highlighting data from EMERALD-1.

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Roswell Park Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Pooja Murthy, MD, discusses second-line treatments in ER+/HER2– metastatic breast cancer for patients following progression on endocrine therapy plus a CDK4/6 inhibitor.

Chih-Yi Liao, MD, discusses the treatment landscape of advanced biliary tract cancer and outlines therapy selection factors.

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy